Stock comparison
Bristol-Myers Squibb
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMY
Bristol-Myers Squibb
Market cap
$116.4B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMY | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 50C | 69B | LMAT |
| Benjamin Graham | 50C | 81A | LMAT |
| Philip Fisher | 39D | 73B | LMAT |
| Peter Lynch | 53C | 59C | LMAT |
| Joel Greenblatt | 27F | 48D | LMAT |
| Charlie Munger | 47D | 60C | LMAT |
| Terry Smith | 44D | 61C | LMAT |
Side-by-side metrics
| Metric | BMY | LMAT |
|---|---|---|
| Market cap | $116.4B | $2.32B |
| P/E (TTM) | 16.0x | 37.1x |
| EV/EBIT | 11.9x | 36.6x |
| ROIC (TTM) | 13.55% | 9.43% |
| Gross margin | 68.75% | 72.39% |
| Net margin | 15.01% | 24.35% |
| Revenue CAGR 5y | 0.96% | 12.75% |
| EPS CAGR 5y | 2.37% | 19.04% |
| Debt / Equity | 2.2x | 0.5x |
| Dividend yield | 4.39% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMY leads on
- Market cap$116.4Bvs $2.32B+98%
- Dividend yield4.39%vs 0.84%+81%
- EV/EBIT11.9xvs 36.6x+67%
- P/E (TTM)16.0xvs 37.1x+57%
LMAT leads on
- Revenue CAGR 5y12.75%vs 0.96%+92%
- EPS CAGR 5y19.04%vs 2.37%+88%
- Debt / Equity0.5xvs 2.2x+79%
- Net margin24.35%vs 15.01%+38%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.